Abstract: 5-Aryl-1,4-dihydropyridines of the formula ##STR1## in which Rrepresents cycloalkyl,heteroaryl oraryl which is optionally substituted by at least one substituent independently selected from the group consisting of halogen, nitro, hydroxyl, amino, carboxyl, alkoxycarbonyl, cyano, acyl, acyloxy, acylthio, by alkyl, alkyloxy, alkylthio or alkylsulphonyl, each of which is optionally substituted by one or more halogens, by aryl which is optionally substituted by alkyl, alkoxy, halogen or nitro, or optionally by the group --Z--CH.sub.2 --R.sup.4,whereZ represents oxygen or sulphur, andR.sup.4represents cycloalkyl,heteroaryl oraryl which is optionally substituted by halogen, cyano, nitro, hydroxyl, carboxyl, alkoxycarbonyl or by alkyl or alkoxy, each of which is optionally substituted by one or more halogens,R.sup.1 and R.sup.2are identical or different andrepresent straight-chain or branched alkyl which is optionally substituted by aryl, carboxyl, alkoxycarbonyl or by hydroxyl,R.sup.

Abstract: Novel cardioactive compounds of the formula ##STR1## in which R.sup.1 is alkyl, aryl or heterocyclic, preferably substituted phenyl,R.sup.2 is alkyl, preferably methyl,R.sup.3 is hydrogen, halogen, acyloxy or alkyl, preferably hydrogen, andR.sup.4 is phenyl, carbalkoxy or together with R.sup.3 forms a ring, preferably carbalkoxy,are produced by reducing the corresponding nitro compounds.

Abstract: Novel circulation active dihydropyridines of the formula ##STR1## in which X is CO, SO.sub.2 or CONH,R.sup.4 is H, OH, alkyl, halogen, acyloxy, alkoxyalkoxy, aralkyloxy, or together with R.sup.5 forms a heterocyclic ring, andthe other radicals are conventional in the dihydropyridine art,and pharmaceutically acceptable salts thereof.

Abstract: Pure enantiomers of 5-nitrodihydropyridine of the formula ##STR1## are mixed, wherein one of the enantiomers has a high vasodilative action and a low negative inotropic activity on heart muscle, the other enantiomer has a low vasoconstrictive action and a high positive inotropic activity on heart muscle, the mixture being high in vasodilative activity and in positive inotropic activity on heart muscle.

Abstract: 1-Oxo-1,3,4,7-tetrahydrobenzofuranes of the formula ##STR1## in which X is O or S,R is optionally substituted phenyl or heteroaryl,R.sup.1 is OH, monoalkylamino or dialkylamino, andR.sup.2 is an acyl or esterified carboxy radical,or pharmacologically acceptable salts thereof, which are active in circulation, e.g. they increase myocardial contractility, increase the flow of Ca.sup.2+ into the cell, increase blood pressure, reduce blood sugar, reduce swelling of mucous membranes and affect the salt and/or fluid balance.

Abstract: Novel compounds of the formula ##STR1## in which R.sup.2 is hydrogen or a substituent, andR.sup.1 is optionally substituted alkyl or alkenyl,exhibit positive inotropic activity on the cardiac muscle, intensifying the contraction power.

Abstract: 1,4-Dihyropyridinecarboxamides of the formula ##STR1## and salts thereof, are effective for treating cardiac insufficiency, thromboses, thromboembolisms and ischaemias, for influencing the blood-sugar level and the circulation and as coronary therapeutic agents and anti-arrhythmic agents.

Abstract: Hydroxytetrahydropyridinelactones of the formula ##STR1## in which R represents a phenyl, naphthyl, thienyl, furyl, pyrryl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, quinolyl, isoquinolyl, indolyl, benzimidazolyl, quinazolyl, quinoxalyl, thionaphthenyl, isothionaphthenyl, chromonyl, thiochromonyl, chromenyl, thiochromenyl, benzoxadiazolyl or benzthiadiazolyl radical, and the stated radicals may carry 1 to 3 identical or different substituents from the group comprising C.sub.1 -C.sub.20 -alkyl, C.sub.2 -C.sub.20 -alkenyl, C.sub.2 -C.sub.20 -alkinyl, C.sub.1 -C.sub.20 -alkoxy, fluorine, chlorine, bromine, iodine, trifluoromethyl, monofluoro-C.sub.1 -C.sub.10 -alkoxy, polyfluoro-C.sub.1 -C.sub.10 -alkoxy, hydroxyl, amino, mono-C.sub.1 -C.sub.10 -alkylamino, di-C.sub.1 -C.sub.10 -alkylamino, nitro, cyano, azido, carboxyl, carb-C.sub.1 -C.sub.10 -alkoxy, carboxamido, sulphonamido, SO.sub.

Abstract: Novel 3-nitro-dihydropyridine derivatives of the formula ##STR1## in which R.sub.1 and R.sub.2 each independently is hydrogen, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.12 -alkoxy, C.sub.1 -C.sub.4 -halogenoalkoxy, halogen, nitro, C.sub.1 -C.sub.4 -halogenoalkyl, C.sub.1 -C.sub.4 -halogenoalkylmercapto, ##STR2## Z is oxygen or sulphur, R.sub.4 and R.sub.5 each independently is hydrogen, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.6 -alkoxy, halogen, C.sub.1 -C.sub.4 -halogenoalkyl, C.sub.1 -C.sub.4 -halogenoalkoxy or nitro, orR.sub.1 and R.sub.2, together with 2 C atoms of the phenyl ring form the ring ##STR3## X is oxygen or sulphur, A is a hydrocarbon radical with up to 12 C atoms which optionally contains one or two identical or different chain members from the group comprising O, S and CO and/or which is optionally substituted by hydroxyl or aliphatic acyloxy with up to 4 C atoms,R.sub.3 is --O--COR.sub.6, --S--CO--R.sub.6, SH, OH , NH.sub.2, ##STR4## NH--COR.sub.6, COOR.sub.6, NR.sub.7 R.sub.8 or CONR.sub.7 R.

Abstract: Tetrahydrothienopyridines of the formula ##STR1## in which R is optionally substituted aryl or heterocyclyl,R.sup.1 is an organic radical, andR.sup.2, R.sup.3 and R.sup.4 each independently is hydrogen or an organic radical, or pharmaceutically acceptable salts thereof, which are coronary active, hypotensive, anti-diabetic and salt balance restoring.

Abstract: Novel chromone-8-aldehydes and thiochromone-8-aldehydes, useful in making pharmaceutically active dihydropyridines, of the formula ##STR1## in which R.sub.1 represents hydrogen, a C.sub.1 -C.sub.10 aliphatic hydrocarbon radical, a C.sub.1 -C.sub.10 alkyl carboxylate, or an aromatic or heteroaromatic ring which optionally has 1-5 identical or different halogen, C.sub.1 -C.sub.10 -alkyl, C.sub.1 -C.sub.10 -alkoxy, C.sub.1 -C.sub.10 -alkylthio, C.sub.1 -C.sub.10 -alkylsulphinyl, cyano, hydroxyl, nitro, C.sub.1 -C.sub.5 -monofluoroalkyl or polyfluoroalkyl, C.sub.1 -C.sub.5 monofluoroalkoxy or polyfluoroalkoxy, C.sub.1 -C.sub.6 monofluoroalkylthio or polyfluoroalkylthio, amino, C.sub.1 -C.sub.5 -monoalkylamino or C.sub.1 -C.sub.5 dialkylamino substituents,R.sub.2 represents hydrogen or 1 to 3 halogen atoms, A represents a single bond, a C.sub.1 -C.sub.20 alkylene chain or a C.sub.2 -C.sub.

Abstract: 4-(Nitrophenyl)-1,2,3,4-tetrahydropyridines of the formula ##STR1## in which R.sub.1 and R.sub.2 are identical or different and each represent hydrogen, phenyl or a straight-chain or branched alkyl radical which is optionally substituted by halogen or alkoxy,R.sub.3 represents a straight-chain or branched alkyl radical which is optionally substituted by alkoxy, halogen, alkylamino or aryl,X represents a single bond, an oxygen atom, a sulphur atom or the NH group andY denotes either the nitrile group or the radical ##STR2## wherein X' corresponds to the definition of X and can either be identical to X or different from X, andR.sub.4 corresponds to the definition of R.sub.3 and can be either identical to R.sub.3 or different from R.sub.3,or physiologically acceptable salts thereof, which are active on the circulation system, for example as vasodilators.

Abstract: The invention relates to pharmaceutical compositions containing active ingredients of Formula (I) and methods for the use of said compositions to treat cardiac insufficiencies. Also included in the invention are methods of the manufacture of said active ingredients of Formula (I). The invention includes, additionally, compounds of Formula (I).

Abstract: A method of combating a disorder of the salt balance in a patient afflicted therewith comprising administering to such patient a salt-balance restoring effective amount of a vasodilating 1,4-dihydropyridine of the formula ##STR1## in which R.sup.1 and R.sup.2 each independently is alkyl with 1 to 4 carbon atoms, and the nitro radical is in the ortho- or meta-position of the phenyl radical.The salt balance disorder may accompany the hypertensive disease or may also be aggravated by administering to such a patient a hypertension reducing agent.

Abstract: Dihydropyridines of the formula ##STR1## in which R.sup.1, R.sup.2, R.sup.5 and R.sup.6 can be hydrogen or various halogen or organic radicals,R.sup.4 is an optionally substituted hydrocarbon radical,A is a direct bond, a C.sub.1 -C.sub.20 -alkylene chain or a C.sub.2 -C.sub.20 -alkenylene chain, which chains are optionally interrupted by O or SX is O or S, andY is a direct bond, O, S, --NH--or--N-alkyl with 1 to 8 C atomsor a pharmaceutically acceptable salt,are useful as cardiotonic agents for improving heart contractility, antihypotonic agents, for lowering the blood sugar level, for detumescing mucous membranes and for influencing the salt and/or liquid balance.

Abstract: Dihydropyridines of the formula ##STR1## in which R.sup.1, R.sup.2, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 can be hydrogen or various halogen or organic radicals,R.sup.4 is an optionally substituted hydrocarbon radical,A is a direct bond, an alkylene chain with 1 to 20 C atoms or an alkenylene chain with 2 to 20 atoms, the chains being optionally interrupted by O or S,X is O or S andY is a direct bond, O, S, -NH- or -N- alkyl with 1 to 8 C atoms,or a pharmaceutically acceptable salt thereof, are useful as cardiotonic agents for improving heart contractility, antihypotonic agents, for lowering the blood sugar level, for detumescing mucous membranes and for influencing the salt and liquid balance.

Abstract: A 1,4-dihydropyridine derivative of the formula ##STR1## in which R and R.sub.1 each independently is hydrogen, C.sub.1 -C.sub.4 -alkyl, C.sub.1 to C.sub.12 -alkoxy, C.sub.1 -C.sub.4 -halogenoalkoxy, halogen, nitro, trifluoromethyl, ##STR2## X is oxygen or sulphur, R.sub.4 and R.sub.5 each independently is hydrogen, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.6 -alkoxy, halogen, trifluoromethyl, amino or nitro, andR.sub.2 and R.sub.3 each independently is hydrogen, a C.sub.1 -C.sub.10 -alkyl, C.sub.2 -C.sub.10 -alkenyl or C.sub.3 -C.sub.10 -alkinyl radical which is optionally substituted by halogen, hydroxyl, C.sub.1 -C.sub.4 -alkoxy, amino, mono- and di-C.sub.1 -C.sub.4 -alkylamino, carbo-C.sub.1 -C.sub.6 -alkoxy and/or nitro, a C.sub.3 to C.sub.6 -membered cycloalkyl radical, a phenyl radical which is optionally substituted by C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.6 -alkoxy, halogen, amino and/or nitro, or a phenyl-C.sub.1 -C.sub.3 -alkyl radical, or a carbohydrate radical which is optionally bonded via a C.

Abstract: Novel 1,4-dihydropyridines of the fomula ##STR1## in which R.sub.1 and R.sub.2 each independently is hydrogen, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.12 -alkoxy, C.sub.1 -C.sub.4 -halogenoalkoxy, halogen, nitro, C.sub.1 -C.sub.4 -halogenoalkyl, C.sub.1 -C.sub.4 -halogenoalkylmercapto, ##STR2## in which Z is oxygen or sulphur, andR.sub.4 and R.sub.5 each independently is hydrogen, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.6 -alkoxy, halogen, C.sub.1 -C.sub.4 -halogenoalkyl, C.sub.1 -C.sub.4 -halogenoalkoxy or nitro, orR.sub.1 and R.sub.2, together with 2 C atoms of the phenyl ring, form the ring ##STR3## X is oxygen, sulphur or the radical NR.sub.6, R.sub.6 is a C.sub.1 -C.sub.6 -alkyl group,A is a C.sub.2 -C.sub.10 -alkylene group, it being necessary that at least two C atoms are located in the alkylene chain which connects the carbonyloxy group to X, andR.sub.

Abstract: 1,4-Dihydropyridines of the formula ##STR1## in which n is 0,1 or 2, andR.sup.1 to R.sup.7 can have a wide variety of meanings, which possess inotropic action, and many of which are new, are useful in increasing the influx of Ca.sup.++ into cells, particularly in combatting coronary and vascular diseases, hypertension swelling in the mucous membranes and diseases involving increased blood sugar or an incorrect salt and fluid balance.

Abstract: 1,4-Dihydropyridines of the formula ##STR1## in which R.sup.1, R.sup.4, R.sup.5, R.sup.6 and Y are hydrogen or various organic radicals,R.sup.2 and R.sup.3 are various organic radicals, ##STR2## is phenyl, naphthyl or various heterocyclic radicals, X is a direct bond, O, S or SO, andB is a direct bond or alkylene,or pharmaceutically acceptable addition salts thereof exhibit hypotensive, vasodilating and coronary activities.